Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) COO Christina Rossi sold 2,274 shares of the business's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $95.02, for a total value of $216,075.48. Following the transaction, the chief operating officer now owns 69,266 shares of the company's stock, valued at approximately $6,581,655.32. The trade was a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Christina Rossi also recently made the following trade(s):
- On Tuesday, January 21st, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $110.14, for a total value of $250,458.36.
Blueprint Medicines Trading Down 1.1 %
Shares of BPMC traded down $1.01 during mid-day trading on Friday, hitting $88.72. 621,251 shares of the company's stock traded hands, compared to its average volume of 729,152. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The firm has a market capitalization of $5.67 billion, a P/E ratio of -82.15 and a beta of 0.58. The business's 50-day moving average price is $98.13 and its 200-day moving average price is $94.04. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90.
Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, sell-side analysts forecast that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the stock. Piper Sandler raised their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Morgan Stanley started coverage on shares of Blueprint Medicines in a research report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price objective on the stock. JPMorgan Chase & Co. upped their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. StockNews.com downgraded Blueprint Medicines from a "hold" rating to a "sell" rating in a research report on Monday, March 3rd. Finally, Wolfe Research started coverage on Blueprint Medicines in a research note on Tuesday, March 18th. They set an "outperform" rating for the company. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $124.95.
Check Out Our Latest Stock Analysis on BPMC
Institutional Trading of Blueprint Medicines
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Blueprint Medicines by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 6,774,884 shares of the biotechnology company's stock worth $590,905,000 after acquiring an additional 91,450 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Blueprint Medicines by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,679,089 shares of the biotechnology company's stock worth $495,331,000 after purchasing an additional 291,822 shares during the period. Wellington Management Group LLP raised its holdings in Blueprint Medicines by 8.0% in the fourth quarter. Wellington Management Group LLP now owns 4,281,364 shares of the biotechnology company's stock worth $373,421,000 after purchasing an additional 316,754 shares in the last quarter. State Street Corp boosted its holdings in shares of Blueprint Medicines by 16.2% during the 3rd quarter. State Street Corp now owns 2,765,702 shares of the biotechnology company's stock valued at $255,827,000 after buying an additional 385,818 shares in the last quarter. Finally, William Blair Investment Management LLC boosted its holdings in shares of Blueprint Medicines by 16.1% during the 4th quarter. William Blair Investment Management LLC now owns 1,944,695 shares of the biotechnology company's stock valued at $169,616,000 after buying an additional 269,896 shares in the last quarter.
About Blueprint Medicines
(
Get Free Report)
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Featured Articles
Before you consider Blueprint Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Blueprint Medicines wasn't on the list.
While Blueprint Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
